NCT05980416 2025-11-14
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
Phase 1 Terminated
Elevation Oncology
Yonsei University
National Cancer Center, Japan
Eli Lilly and Company
Eli Lilly and Company